Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.68 |
| ▸ | MAOB | P27338 | 11/20 | 0.67 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044912 | 0.88 | FFAR1 (0.86) | FFAR1MAOBPARP10NR4A2 | |
| SCHEMBL5038715 | 0.84 | FFAR1 (0.64) | FFAR1MAOBPARP10NR4A2MAOA | |
| SCHEMBL9935190 | 0.83 | FFAR1 (0.65) | FFAR1MAOBPARP10NR4A2MAOA | |
| SCHEMBL9933192 | 0.82 | FFAR1 (0.81) | FFAR1 | |
| SCHEMBL3503549 | 0.81 | MAOB (1.00) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL9934278 | 0.80 | FFAR1 (0.83) | FFAR1 | |
| SCHEMBL4423295 | 0.78 | MAOB (0.71) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL4427972 | 0.78 | MAOB (0.71) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL26106027 | 0.77 | NR4A2 (0.74) | FFAR1MAOBPARP10NR4A2MAOA | |
| SCHEMBL3625818 | 0.77 | MAOB (0.73) | MAOBPARP10NR4A2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1523469-B1 | CINNAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-6900354-B2 | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1523469-A1 | CINNAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-04-20 | — | — | EP | disclosed |
| US-20040034096-A1 | 3-Phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004007429-A1 | CINNAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | FFAR1 642/4885MAOB 1/4885PARP10 833/4885 |
| US-20040034096-A1 | 3-Phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives | MAOB, MAOA, APP | FFAR1 2999/4885MAOB 1/4885PARP10 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.